Health Research Institute of Navarra (IdiSNA), Pamplona, Navarra, Spain; Solid Tumor Program, Center for the Applied Medical Research (CIMA), Pamplona, Navarra, Spain; Department of Pediatrics, Clínica Universidad de Navarra (CUN), Pamplona, Navarra, Spain.
Int Rev Cell Mol Biol. 2023;379:169-188. doi: 10.1016/bs.ircmb.2023.04.001. Epub 2023 Apr 26.
High-grade gliomas (HGGs) are the most common and aggressive primary brain tumors in both adult and pediatric populations. Despite the multimodal treatment modality currently available for HGG, the prognosis is dismal, with a low overall survival rate at two years after diagnosis. In the last decade, oncolytic virotherapy has emerged as a promising and feasible therapeutic tool in management of these tumors due to its oncolytic and immunostimulatory properties. Various oncolytic viruses, such as herpes simplex virus, adenovirus, poliovirus, reovirus, parvovirus and others, have been evaluated in the early stages of the clinical setting with regard to improving the outcome of patients with HGG. In this review, we summarize completed and ongoing clinical trials of oncolytic virotherapy for adult and pediatric malignant gliomas in terms of safety and efficacy, followed by a brief discussion about the current status and future directions of this therapy in the brain tumor field.
高级别胶质瘤（HGG）是成人和儿童中最常见且侵袭性最强的原发性脑肿瘤。尽管目前针对 HGG 有多种治疗方式，但预后仍不容乐观，诊断后两年的总体生存率很低。在过去十年中，溶瘤病毒治疗因其溶瘤和免疫刺激特性而成为管理这些肿瘤的一种很有前途和可行的治疗工具。已经在临床早期评估了各种溶瘤病毒，如单纯疱疹病毒、腺病毒、脊髓灰质炎病毒、呼肠孤病毒、细小病毒等，以期改善 HGG 患者的预后。在这篇综述中，我们总结了已完成和正在进行的针对成人和儿童恶性脑胶质瘤的溶瘤病毒治疗的临床试验，从安全性和有效性方面进行了总结，随后简要讨论了该疗法在脑肿瘤领域的现状和未来方向。
